



PATENT  
ATTORNEY DOCKET NO. 50304/062001

Certificate of Mailing: Date of Deposit: April 15, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Heidi J. Wright

Printed name of person mailing correspondence

  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	JACQUEMIN et al.	Art Unit:	1544
Serial No.:	10/030,522	Examiner:	Maher M. Haddad
Filed:	May 2, 2002	Customer No.:	21559
Title:	LIGANDS FOR USE IN THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HEMOSTASIS DISORDERS		

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION OF DR. MARC G. JACQUEMIN

I declare:

1. I am a co-inventor of the subject matter described and claimed in the above-captioned patent application.
2. The publications Jacquemin *et al.* (Blood 92: 710 (Abstract # 2917); November 1998; copy attached) and Gilles *et al.* (Blood 92: 710 (Abstract # 2919); November 1998; copy attached) were published in November 1998, not more than one year before the July 14, 1999 filing date of applicants' priority application, U.S. Serial No. 60/143,891.

3. The experiments described in the Jacquemin *et al.* and Gilles *et al.* abstracts that relate to the invention were the joint contributions of the instant inventors alone, notwithstanding the inclusion of the additional authors on the abstracts. The other named authors J.G.G. Gilles, A. Benhida, B. Desqueper, and R. Lavend'homme were working under the direction of the named inventors, and did not contribute to the claimed inventive matter. In addition, K. Peerlinck, M. Hoylaerts, S. Jerieux, and C. Mazurier provided materials to the named inventors in order to conduct the experiments described in the Jacquemin *et al.* and Gilles *et al.* abstracts, and did not contribute to the claimed inventive matter. Finally, as a professional courtesy, Dr. Jos Vermeylen was included as an author as he was, at that time, the head of the Center for Molecular and Vascular Biology, University of Leuven; he did not contribute to the claimed inventive matter.

4. All statements made herein of my knowledge are true and all statements made on information and belief are believed to be true; and further these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: April 15, 2005  
Dr. Marc G. Jacquemin

## Abstract 2917

**MUTATION ARG2150 → HIS IN THE FACTOR VIII C1 DOMAIN ALTERS THE BINDING OF FACTOR VIII TO VON WILLEBRAND FACTOR AND IS RESPONSIBLE FOR A MILD HEMOPHILIA A PHENOTYPE.** M.G. Desqueyres<sup>1</sup>, K. Peerlinck<sup>2</sup>, J.G. Gilles<sup>1</sup>, A. Benhida<sup>1</sup>, B. Desqueyres<sup>1</sup>, R. Laveand'homme<sup>1</sup>, J. Vermeylen<sup>1</sup>, J.M.R. Saint-Remy. *Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven, Belgium.*

Although mutations located in the factor VIII (FVIII) C1 domain have been identified in patients with mild/moderate hemophilia A, the role of this domain in FVIII function or stability remains unknown. We have investigated the possible role of C1 in FVIII interaction with vWF by using a human monoclonal antibody recognizing the C1 domain and plasma FVIII (~0.1 IU/ml) of mild hemophilia A patients carrying the mutation Arg2150 → His. An IgG4 human monoclonal antibody, LE2E9, was obtained by *in vitro* immortalisation of memory B lymphocytes of a mild hemophilia A patient (LE) who developed an immune response towards wild type FVIII but remained tolerant towards self FVIII carrying the mutation Arg2150 → His. Epitope mapping with recombinant FVIII domains demonstrated that LE2E9 recognises only wild type FVIII to LE2E9 and its Fab fragment completely inhibited the binding of wild type FVIII to vWF, suggesting that the C1 epitope recognised by this antibody may contribute to the binding of FVIII to vWF. Direct evidence that residue Arg2150 is important for the interaction of FVIII with vWF was obtained by demonstrating an alteration of the binding of patient LE's FVIII to vWF. When plasma vWF/FVIII complexes were captured on a Sepharose column coated with an anti-vWF monoclonal antibody, 95% of FVIII present in normal plasma remained bound to the Sepharose but only 78% of LE FVIII. In addition, the dissociation rate constant of the FVIII/vWF complex was higher for LE than for normal FVIII: the dissociation half-time of normal and LE FVIII/vWF complexes were 16 min and 4 min, respectively. In patient LE's plasma, the FVIII level measured by clotting assay was identical to the level of FVIII antigen detected by ELISA, indicating that LE FVIII molecules had a normal specific activity in coagulation assays and that the low FVIII level in the patient's plasma was due to either reduced synthesis or altered clearance of FVIII. Similar results were obtained with plasma of patient LE's hemophilic brother and one unrelated hemophilic carrying the same mutation, Arg2150 → His. Altogether, these results indicate that the C1 domain is involved in FVIII binding to vWF and suggest that the reduced affinity of FVIII for vWF contribute to the low levels of circulating FVIII in patients with mutation Arg2150 → His.

## Abstract 2918

**CHARACTERIZATION OF TWO NATURALLY OCCURRING MUTATIONS IN THE SECOND EGF-LIKE DOMAIN OF FACTOR VII.** M. Hunsault<sup>1</sup>, A.A. Arbini<sup>2</sup>, J.A. Carew<sup>1</sup>, F. Peyvandi<sup>1</sup>, K.A. Bauer. *Bracton West Roxbury VA Medical Center; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.*

We investigated the molecular basis underlying severe factor VII (FVII) deficiency in two Italian patients with moderate to severe bleeding disorders. Sequencing demonstrated that both were homozygous and had missense mutations in exon 5, which codes for the second EGF-like domain of FVII. Their FVII levels and genotypes (including the Arg353Gln and deca-nucleotide insert at nucleotide -323 in the 5'-flanking region) are tabulated below:

Missense Mutation	VII:Ag	VII:C	Arg353Gln	-323 Insert
G→T 782A, Gly97Cys	2%	<1%	+	+
→G 783A, Gln100Arg	12%	<1%	-	-

Transient transfections were performed in COS-1 cells with wild type (wt) and mutant FVII cDNAs in the pCD vector with measurement of FVII levels in cell lysates (L) and conditioned media (CM).

	FVIIwt (N=8)	FVIIcys97 (N=8)	FVIIarg100 (N=8)
L VII:Ag	100 ± 2.8	38.1 ± 3.9	54.6 ± 3
CM VII:Ag	100 ± 3	6.6 ± 0.5	16.7 ± 2.1
CM VII:C	100 ± 2.9	6.1 ± 0.3	2.8 ± 0.2

The FVIIcys97 and FVIIarg100 mutations result in defective secretion; the Arg100 mutation also affects FVII function since VII:C is lower than VII:Ag both *in vivo* and *in vitro*. Using stably transfected CHO cells, metabolic labeling studies demonstrated that FVIIwt in cell lysates was maximal 30-60 min after the pulse and decreased as FVII was secreted. FVIIcys97 and FVIIarg100 persisted intracellularly for a longer period of time than FVIIwt (40% and 55% of the intracellular amount of intracellular FVIIcys97 and FVIIarg100, respectively, were still present 240 min after the end of the labeling period as compared to 12% for FVIIwt). Immunohistochemical studies showed that FVIIarg100 was present diffusely in the cytoplasm suggesting predominant localization in the endoplasmic reticulum, while FVIIwt and FVIIcys97 stained mostly in the perinuclear area indicating its transit to the Golgi complex. Experiments using inhibitors of protein degradation suggested that FVIIcys97 was degraded in a pre-Golgi, non-lysosomal compartment by a cysteine protease, while FVIIarg100 was retained in lysosomal compartment for a longer period of time than FVIIwt. In CM under non-denaturing conditions, FVIIarg100 had a lower apparent molecular weight than FVIIwt which likely results from misfolding of the protein due to abnormal disulfide bond formation.

## Abstract 2919

**THE ARG 2150 HIS MUTATION WITHIN THE FACTOR VIII C1 DOMAIN ELIMINATES A B CELL EPITOPE THAT IS PRESENT ONLY ON FACTOR VIII-VON WILLEBRAND FACTOR COMPLEXES.** J.G. Gilles<sup>1</sup>, R. Laveand'homme<sup>1</sup>, K. Peerlinck<sup>2</sup>, M. Jacquemin<sup>1</sup>, M. Hoylaerts<sup>1</sup>, S. Jorjoux<sup>1</sup>, C. Mazurier<sup>1</sup>, J. Vermeylen<sup>1</sup> and J.-M. Saint-Remy. *Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium; Laboratoire Français de Fractionnement et des Biotechnologies, Lille, France.*

A mild hemophilia A patient (LE) with an Arg2150His mutation in the C1 domain of the factor VIII (FVIII) light chain was shown to have anti-FVIII antibodies inhibiting allogeneic but not self FVIII in a one-stage coagulation assay. Additionally, the inhibitory activity of such antibodies was much increased in the presence of von Willebrand factor (vWF). Polyclonal anti-FVIII antibodies of this patient were purified by affinity adsorption using recombinant FVIII (rFVIII) or plasma-derived (pd) FVIII-vWF complexes. The rFVIII immunosorbent eluate contained an inhibitory activity to allogeneic FVIII, but not to self FVIII with a elution comparable to that found in the total IgG fraction used for the adsorption procedure. The same IgG fraction sequentially passed through a pdFVIII and rFVIII-immunosorbent showed that adsorption on pdFVIII captured antibodies exhibiting split reactivity between wild-type FVIII and mutated Arg2150His FVIII, and that such antibodies were not retained by rFVIII immunosorbent. In addition, in ELISA, this fraction showed an important increased binding capacity to FVIII-vWF when compared to FVIII. These selectively inhibiting antibodies were shown to belong to the IgG2 isotype. To explain why vWF-dependent antibodies recognised wild-type but not self FVIII, the interaction between mutated FVIII and vWF was evaluated. The data indicated that a clinically-relevant FVIII B cell epitope generated by the association of FVIII with vWF is lost on the Arg2150His mutation. Patients carrying such an Arg2150His mutation and receiving FVIII molecule. Patients carrying such an Arg2150His mutation and receiving infusion of wild-type FVIII may therefore be at risk of developing inhibitors to allogeneic FVIII only. This point mutation in the FVIII light chain offers the first example of clinically-relevant FVIII B cell epitope(s) generated by the association of FVIII with vWF.

## Abstract 2920

**INTRACELLULAR AND EXTRA-CELLULAR INSTABILITY OF A NOVEL Y283C MUTANT OF THE A SUBUNIT FOR COAGULATION FACTOR XIII CAUSED BY IMPAIRED PROTEIN FOLDING, DIMER FORMATION, AND HETEROTETRAMER ASSEMBLY.** M. Sourif<sup>1</sup>, K. Kassi<sup>1</sup>, T. Kaneshiro<sup>1</sup>, K. Narasaka<sup>1</sup>, G. Castaman<sup>1</sup>, V.C. Yee<sup>2</sup> and A. Ichikawa. *Department of Molecular Pathological Biochemistry and Biology, Yamagata University School of Medicine, Yamagata, Japan; 1 Department of Hematology, San Borromeo Hospital, Vercelli, Italy; 2 Lerner Research Institute, Cleveland Clinic Foundation Cleveland OH 44195, USA.*

Coagulation factor XIII (FXIII), a plasma transglutaminase, is a heterotetramer consisting of two catalytic A subunits (XIIIA) and two nonenzymatic B subunits (XIIB). In the present study, a novel mutation in the XIIIA gene, Y283C, was identified in a patient with FXIII deficiency. A recombinant Y283C protein was found to be labile when it was expressed in MEG-01 cells which can endogenously synthesize XIIIA. We also characterized in detail the Y283C mutant as well as two other mutants, G562R and I464stop, previously identified by Takahashi et al. (Blood 91: 2830-2838, 1998). All these mutants exhibited decreased thermal stability and resistance against proteolytic cleavage when compared with a wild-type XIIIA. Gel-filtration analysis revealed that the mutants were in a monomer form, while the wild-type was in a dimer form. These results were consistent with the prediction by molecular modeling that the mutant molecules are misfolded and/or destabilized. Although assembly of a heterotetramer with XIIB was demonstrated for Y283C by both gel-filtration analysis and a co-immunoprecipitation method using anti-XIIB antibody, its binding ability was 10% that of the wild-type. No complex formation was observed for the G562R and I464stop mutants. The wild-type XIIIA was stabilized in plasma by the complex formation with XIIB, and the XIIIA complexed with XIIB was more resistant against proteolytic cleavage. On the other hand, mutant XIIBs were unstable in plasma even in the presence of XIIB. Thus, impaired folding, dimer formation, and heterotetramer assembly of the mutant XIIBs lead to both intra- and extra-cellular instability, which is responsible for XIIIA deficiency in the patients.

## Abstract 2921

**VON WILLEBRAND DISEASE TYPE 2M VICENZA IN ITALIAN AND GERMAN PATIENTS - THE FIRST CANDIDATE MUTATIONS.** R. Schneppenheim<sup>1</sup>, A.B. Federici<sup>1</sup>, U. Budde<sup>2</sup>, G. Castaman<sup>1</sup>, B. Drowatz<sup>1</sup>, S. Krey<sup>1</sup>, P.M. Mannucci<sup>1</sup>, G. Riesen<sup>1</sup>, F. Rodighiero<sup>1</sup>, B. Zieger<sup>1</sup>, R. Zimmetmann<sup>1</sup>. *University Children's Hospital, Hamburg; University Children's Hospital Freiburg; Kurpfalzlinik, Heidelberg, Germany; Hemophilia and Thrombosis Center, University of Milan; Division of Hematology, Vercelli, Italy.*

Von Willebrand disease (VWD) type 2, is caused by structural and functional defects of the von Willebrand factor (vWF). VWD type 2M (Vicenza) is characterized by autosomal dominant inheritance, low vWF:Ag and the presence of "supernormal" multimers in plasma. In the formerly described Italian patients (Mannucci et al. Blood 71:63-70, 1988), the molecular defect is linked to the vWF gene (Rendi et al. Thromb Haemostasis 69:173-176 1993). However, no specific mutations have been identified until now. As part of a mutation screening program